REG - Partners Grp Pvt Eqt Partners Grp E-PEYS - NAV increased by 0.5% in January

Partners Private EquityAnnouncement

07/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250307:nRSG8001Za&default-theme=true

RNS Number : 8001Z  Partners Group Private Equity Ltd  07 March 2025

(LSE: PEYS/PEY)

 

Partners Group Private Equity Limited

 

NAV increased by 0.5% in January

 

 

·    NAV increased by 0.5% to EUR 1'044.1 million corresponding to EUR
15.10 per share

·    Positive value creation (0.8%), slightly offset by currency movements
(-0.3%)

·    PGPE Ltd invested EUR 2.2 million during the reporting period

 

From the total EUR 2.2 million invested by PGPE Ltd in January, EUR 1.6
million was in Avid Bioservices ("Avid"), a US-based biologics contract
development and manufacturing organization ("CDMO") specializing in
small-batch production of complex mammalian proteins. Founded in 1981, Avid
transitioned to a CDMO model in 2018 and now operates four facilities in
California with over 370 employees. The company has a strong reputation in a
niche sector and benefits from robust organic growth and revenue visibility.
Partners Group has strong conviction in CDMOs, having tracked such companies
for several years now as part of the firm's thematic research under the Health
& Life vertical.

 

At the portfolio level, KinderCare Learning Companies ("KinderCare") and
Galderma, both of which began trading on the public market in 2024, were the
top contributors to value creation during the month. The largest for-profit
provider of early childhood education and care services in the US released
the "2025 KinderCare CHRO Perspectives Survey", conducted by the Harris Poll.
The report highlights human resources leaders' recognition of the critical
role childcare benefits play in talent acquisition, retention, and employee
well-being, while underscoring the urgent need for more flexible and
customizable options.

 

Further, Galderma, a pure-play dermatology category leader, recently,
announced the latest updates from its innovative aesthetics portfolio at the
International Master Course on Aging Science (IMCAS) World Congress 2025,
including treatments for frown lines (Relfydess), facial filler (Restylane),
and biostimulator (Sculptra). Meanwhile, Nemluvio (nemolizumab) has received
marketing authorization in the UK and Switzerland for moderate-to-severe
atopic dermatitis and prurigo nodularis.

 

 

Further information is available in the monthly report, which can be accessed
via:
https://www.partnersgroupprivateequitylimited.com/en/investor-relations/financial-reports

 

Ends.

 

About Partners Group Private Equity Limited

PGPE Ltd (formerly Princess Private Equity Holding Limited) is an investment
holding company founded in 1999 and domiciled in Guernsey. It invests in
private equity direct investments. PGPE Ltd is managed in its investment
activities by Partners Group, a global private markets investment management
firm with over USD 150 billion in investment programs under management in
private markets, of which USD 78 billion is in private equity. Partners Group
itself is listed at the Swiss Stock Exchange (ticker: PGHN).  PGPE Ltd aims
to provide shareholders with long-term capital growth and an attractive
dividend yield. PGPE Ltd is traded on the Main Market of the London Stock
Exchange (ticker: PEY for the Euro Quote; PEYS for the Sterling Quote).

 

Contacts

Partners Group Private Equity Limited:

pgpe-ltd@partnersgroup.com

www.partnersgroupprivateequitylimited.com

 

 Investor relations contact:                  Media relations contact:

 Andreea Mateescu                             Jenny Blinch

 Phone: +41 41 784 66 73                      Phone: +41 41 784 65 26

 E-mail: andreea.mateescu@partnersgroup.com   E-mail: jenny.blinch@partnersgroup.com

 

Registered Number: 35241   LEI: 54930038LU8RDPFFVJ57

Notes:

1.     Note that references in this announcement to Partners Group Private
Equity Limited have been abbreviated to "PGPE Ltd" or "Company". References to
Partners Group AG have been abbreviated to "Partners Group" or "Investment
Manager".

2.     This document does not constitute an offer to sell or a
solicitation of an offer to buy or subscribe for any securities and neither is
it intended to be an investment advertisement or sales instrument of Partners
Group Private Equity Limited. The distribution of this document may be
restricted by law in certain jurisdictions. Persons into whose possession this
document comes must inform themselves about and observe any such restrictions
on the distribution of this document. In particular, this document and the
information contained therein is not for distribution or publication, neither
directly nor indirectly, in or into the United States of America, Canada,
Australia or Japan.

3.   This document may have been prepared using financial information
contained in the books and records of the product described herein as of the
reporting date. This information is believed to be accurate but has not been
audited by any third party. This document may describe past performance, which
may not be indicative of future results. No liability is accepted for any
actions taken on the basis of the information provided in this document.
Neither the contents of PGPE Ltd' website nor the contents of any website
accessible from hyperlinks on PGPE Ltd' website (or any other website) is
incorporated into, or forms part of, this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRPKOBDABKKKNK